Nkarta (NKTX) Competitors $2.15 +0.02 (+0.94%) Closing price 04:00 PM EasternExtended Trading$2.15 0.00 (0.00%) As of 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NKTX vs. IVA, ETON, ORKA, CMPS, CRVS, ZVRA, ESPR, ORGO, CMPX, and BCYCShould you be buying Nkarta stock or one of its competitors? The main competitors of Nkarta include Inventiva (IVA), Eton Pharmaceuticals (ETON), Oruka Therapeutics (ORKA), COMPASS Pathways (CMPS), Corvus Pharmaceuticals (CRVS), Zevra Therapeutics (ZVRA), Esperion Therapeutics (ESPR), Organogenesis (ORGO), Compass Therapeutics (CMPX), and Bicycle Therapeutics (BCYC). These companies are all part of the "pharmaceutical products" industry. Nkarta vs. Its Competitors Inventiva Eton Pharmaceuticals Oruka Therapeutics COMPASS Pathways Corvus Pharmaceuticals Zevra Therapeutics Esperion Therapeutics Organogenesis Compass Therapeutics Bicycle Therapeutics Inventiva (NASDAQ:IVA) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability. Is IVA or NKTX more profitable? Inventiva's return on equity of 0.00% beat Nkarta's return on equity.Company Net Margins Return on Equity Return on Assets InventivaN/A N/A N/A Nkarta N/A -27.74%-22.38% Do insiders and institutionals believe in IVA or NKTX? 19.1% of Inventiva shares are owned by institutional investors. Comparatively, 80.5% of Nkarta shares are owned by institutional investors. 32.0% of Inventiva shares are owned by insiders. Comparatively, 8.4% of Nkarta shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts rate IVA or NKTX? Inventiva presently has a consensus target price of $15.57, indicating a potential upside of 149.54%. Nkarta has a consensus target price of $13.60, indicating a potential upside of 532.56%. Given Nkarta's stronger consensus rating and higher possible upside, analysts clearly believe Nkarta is more favorable than Inventiva.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inventiva 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63Nkarta 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.75 Does the media prefer IVA or NKTX? In the previous week, Inventiva had 10 more articles in the media than Nkarta. MarketBeat recorded 11 mentions for Inventiva and 1 mentions for Nkarta. Inventiva's average media sentiment score of 0.21 beat Nkarta's score of -0.21 indicating that Inventiva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inventiva 3 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nkarta 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better earnings & valuation, IVA or NKTX? Nkarta has lower revenue, but higher earnings than Inventiva. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInventiva$9.95M59.99-$199.34MN/AN/ANkartaN/AN/A-$108.79M-$1.48-1.45 Which has more risk & volatility, IVA or NKTX? Inventiva has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500. Comparatively, Nkarta has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. SummaryInventiva beats Nkarta on 7 of the 13 factors compared between the two stocks. Get Nkarta News Delivered to You Automatically Sign up to receive the latest news and ratings for NKTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NKTX vs. The Competition Export to ExcelMetricNkartaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$152.71M$3.34B$6.10B$10.61BDividend YieldN/A2.28%5.64%4.70%P/E Ratio-1.4522.1685.6627.12Price / SalesN/A264.73526.70205.97Price / CashN/A46.3226.3031.12Price / Book0.379.9412.906.66Net Income-$108.79M-$52.35M$3.30B$275.95M7 Day Performance3.86%5.93%4.79%3.31%1 Month Performance-4.87%11.57%8.10%10.75%1 Year Performance-45.15%24.90%75.73%33.53% Nkarta Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NKTXNkarta2.3634 of 5 stars$2.15+0.9%$13.60+532.6%-45.7%$152.71MN/A-1.45140Analyst DowngradeHigh Trading VolumeIVAInventiva3.3386 of 5 stars$5.87-3.0%$14.83+152.7%+248.9%$578.76M$9.95M0.00100Gap DownHigh Trading VolumeETONEton Pharmaceuticals2.242 of 5 stars$22.48+5.7%$29.67+32.0%+184.7%$570.41M$39.01M-140.5020High Trading VolumeORKAOruka Therapeutics3.0505 of 5 stars$19.29+26.9%$42.00+117.7%-22.3%$569.25MN/A-6.86N/AHigh Trading VolumeCMPSCOMPASS Pathways3.3037 of 5 stars$5.87+1.2%$16.29+177.4%+3.5%$556.46MN/A-3.19120CRVSCorvus Pharmaceuticals1.4675 of 5 stars$7.28-1.5%$13.00+78.6%+27.5%$550.66MN/A-7.2130Positive NewsZVRAZevra Therapeutics2.7264 of 5 stars$9.54-2.4%$24.00+151.6%+35.4%$548.44M$23.61M-45.4320Analyst DowngradeESPREsperion Therapeutics3.8658 of 5 stars$2.64-0.4%$7.00+165.2%+52.8%$534.30M$332.31M-5.39200ORGOOrganogenesis3.7896 of 5 stars$4.26+3.9%$7.33+72.1%+39.3%$520.12M$482.04M-30.43950CMPXCompass Therapeutics2.1317 of 5 stars$3.82+2.1%$13.88+263.2%+91.7%$517.18MN/A-8.4920News CoveragePositive NewsAnalyst ForecastBCYCBicycle Therapeutics3.493 of 5 stars$7.61+2.8%$22.22+192.0%-64.5%$512.87M$35.28M-2.17240 Related Companies and Tools Related Companies Inventiva Competitors Eton Pharmaceuticals Competitors Oruka Therapeutics Competitors COMPASS Pathways Competitors Corvus Pharmaceuticals Competitors Zevra Therapeutics Competitors Esperion Therapeutics Competitors Organogenesis Competitors Compass Therapeutics Competitors Bicycle Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NKTX) was last updated on 10/6/2025 by MarketBeat.com Staff From Our Partners1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredWall Street legend: “Sell this A.I. stock now”Whats next after AI? Hidden AI. "Hidden AI" could soon be the biggest investment trend of 2025.Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nkarta, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nkarta With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
